Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.
Michael T HenekaDouglas GolenbockEicke LatzDave MorganRobert BrownPublished in: Alzheimer's research & therapy (2020)
Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. While these symptoms arise acutely during the course of infection, less is known about the possible long-term consequences for the brain. Severely affected COVID-19 cases experience high levels of proinflammatory cytokines and acute respiratory dysfunction and often require assisted ventilation. All these factors have been suggested to cause cognitive decline. Pathogenetically, this may result from direct negative effects of the immune reaction, acceleration or aggravation of pre-existing cognitive deficits, or de novo induction of a neurodegenerative disease. This article summarizes the current understanding of neurological symptoms of COVID-19 and hypothesizes that affected patients may be at higher risk of developing cognitive decline after overcoming the primary COVID-19 infection. A structured prospective evaluation should analyze the likelihood, time course, and severity of cognitive impairment following the COVID-19 pandemic.
Keyphrases
- cognitive decline
- sars cov
- coronavirus disease
- end stage renal disease
- mild cognitive impairment
- cognitive impairment
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- traumatic brain injury
- liver failure
- respiratory syndrome coronavirus
- sleep quality
- depressive symptoms
- hepatitis b virus
- white matter
- cerebral ischemia
- blood brain barrier
- patient reported outcomes
- intensive care unit
- subarachnoid hemorrhage
- acute respiratory distress syndrome
- functional connectivity